Anjarium Biosciences AG, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor capital (a citadel company). The proceeds will be used to develop novel non-viral gene therapies.
Anjarium is focused on creating and delivering a new class of non-viral gene therapies. Its innovative approach leverages breakthrough science and expertise at the interface of generic medicine, synthetic biology and nanoparticle engineering to rationally design and produce tissue-targeted gene therapies — optimized to improve patient outcomes in a range of serious genetic diseases.
The proceeds from the Series A financing will enable Anjarium to expand its team, develop its platform, and push serval therapeutic pipeline programs towards clinical trials.
The Baker McKenzie team, which advised the consortium of VC funds in all legal aspects of the closing of the financing round, was led by Martin Frey (Partner, Zurich) and Kevin Ardüser (Associate, Zurich).